A Blood Test for Alzheimer’s Treatment: Plasma Biomarkers Track Lecanemab’s Real-World Impact
A new multicenter real-world study demonstrates the effectiveness and safety of lecanemab in a Chinese Alzheimer’s disease population, while validating a key role for laboratory medicine in therapeutic monitoring. The research, published in Alzheimer’s & Dementia, followed 261 patients receiving the anti-amyloid antibody. Beyond confirming attenuated cognitive decline, the study provided critical analytical data on plasma biomarkers, including amyloid-beta species, phosphorylated tau 217 (p‑tau217), and glial fibrillary acidic protein (GFAP). Notably, reductions in plasma p‑tau217 showed a strong correlation with amyloid clearance on PET imaging, with nearly 30% of patients turning amyloid-negative. This work underscores the evolving utility of advanced immunoassays and molecular diagnostics in neurology, moving beyond diagnosis into real-time assessment of treatment response and drug efficacy in diverse clinical settings.
Study Significance: For professionals in laboratory medicine and clinical chemistry, this study highlights the transition of plasma biomarkers from research tools to essential components of therapeutic drug monitoring and personalized neurology. The correlation between p‑tau217 levels and imaging outcomes suggests that high-sensitivity immunoassays could reduce reliance on costly and invasive PET scans for routine monitoring. This shift necessitates robust assay validation, stringent quality control, and the integration of these novel tests into established laboratory workflows and diagnostic algorithms to support clinical decision-making.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
